Improving Blood Pressure Control in Patients with Diabetes Mellitus and High Cardiovascular Risk

Table 2

Rates (per 100 patient years) for individual end-points.

End-point	Without diabetes			With diabetes			^∗𝑃-value
	Nifedipine	Placebo	Hazard ratio (95% C. I.)	Nifedipine	Placebo	Hazard ratio (95% C. I.)
All-cause death	1.53	1.43	1.07 (0.89, 1.28)	2.27	2.15	1.05 (0.74, 1.51)	.942
Myocardial Infarction	1.36	1.25	1.09 (0.9, 1.32)	2.02	2.28	0.89 (0.61, 1.29)	.326
Heart Failure	0.37	0.51	0.72 (0.52, 1.01)	1.01	1.52	0.67 (0.41, 1.49)	.771
Stroke	0.33	0.49	0.67 (0.47, 0.94)	0.9	0.73	1.22 (0.67, 2.23)	.086
Coronary Artery Bypass Grafting	1.46	1.92	0.76 (0.64, 0.9)	2.61	2.92	0.9 (0.64, 1.25)	.395
Percutaneous Coronary Intervention	2.08	2.21	0.94 (0.81, 1.1)	2.57	3.11	0.83 (0.59, 1.15)	.482
Peripheral Revascularisation	0.72	0.56	1.27 (0.96, 1.67)	1.21	1.05	1.16 (0.7, 1.94)	.749
Refractory Angina	0.76	0.86	0.89 (0.7, 1.14)	1.09	1.50	0.73 (0.45, 1.18)	.47
Coronary Angiography	5.22	6.29	0.83 (0.75, 0.92)	6.93	9.28	0.75 (0.61, 0.93)	.384

^∗𝑃-value for diabetes status/treatment interaction term.